Sun Pharma to Acquire US-Based Organon in $11.75 Billion Deal, One of India’s Biggest Overseas Acquisitions; Share Price Jumps Nearly 7%

The Indian equity markets are trading in the green on Monday, with the Nifty 50 rising 0.64 per cent. Pharma stocks are also witnessing strong buying interest, with the Nifty Pharma index gaining 2.29 per cent during the session. Amid this positive momentum, Sun Pharmaceutical Industries was trading at Rs 1,730.20, up Rs 109.80 or 6.78 per cent, following a major global acquisition announcement by the company.

Sun Pharma Acquisition Update

Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Co., a New York Stock Exchange-listed global pharmaceutical company, in an all-cash transaction. The deal values Organon at an enterprise valuation of USD 11.75 billion, while Organon shareholders will receive USD 14 per share in cash.

Sun Pharma will acquire 100 per cent of Organon’s outstanding shares, and the transaction is expected to close in early 2027, subject to regulatory approvals and Organon shareholder approval.

Strategic Significance of the Deal

The proposed acquisition is aligned with Sun Pharma’s long-term strategy of strengthening and diversifying its global pharmaceutical business. With this deal, the combined entity is expected to become among the top 25 global pharmaceutical companies with a combined revenue of USD 12.4 billion. The transaction also marks Sun Pharma’s strategic entry into the global biosimilars market as a top-10 player, while significantly strengthening its presence in women’s health and established branded medicines.

Post acquisition, the combined business will have a commercial presence in 150 countries, including 18 markets generating over USD 100 million revenue each, materially expanding Sun Pharma’s international scale.

Management Commentary

“This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform,” said Dilip Shanghvi, Executive Chairman of Sun Pharma.

Kirti Ganorkar, Managing Director of Sun Pharma, added that the transaction is a logical next step in strengthening the company’s global business and offers significant revenue synergy opportunities over the coming years.

About Organon

Organon is a global healthcare company spun off from Merck in 2021 and operates across women’s health, biosimilars, and established branded medicines. The company has a commercial presence in over 140 countries, employs around 10,000 people, and operates six manufacturing facilities globally.

For CY2025, Organon reported USD 6.2 billion in revenue and Adjusted EBITDA of USD 1.9 billion, making it a strategically large-scale international acquisition for Sun Pharma.

About Sun Pharmaceutical Industries

Sun Pharmaceutical Industries is India’s largest pharmaceutical company and one of the world’s leading specialty generics players, with businesses spanning innovative medicines, generics, and consumer healthcare. The company has a strong global presence across over 100 countries and continues to expand its specialty and innovation-led portfolio.

This acquisition is expected to materially strengthen Sun Pharma’s global leadership position and long-term earnings diversification.

Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.